. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2017 Sep 1;23(12):2102–2109. doi: 10.1016/j.bbmt.2017.08.025

Table 2.

Outcomes of Patients in Group 1 with and without Normalization of Pulmonary Function and Patients in Group 2

Characteristic	Group 1 (n = 188)	Normalization		P Value^*	Group 2 (n = 120)	P Value^†
Characteristic	Group 1 (n = 188)	Yes (n = 51)	No (n = 137)	P Value^*	Group 2 (n = 120)	P Value^†
Acute GVHD, n (%)^‡	57 (30)	16 (31)	41 (30)	.86	31 (26)	.44
Chronic GVHD, n (%)	53 (28)	12 (24)	41 (30)	.47	25 (21)	.18
PC, n (%)	80 (43)	13 (26)	67 (49)	.005	37 (31)	.04
Noninfectious PC, n (%)	14 (8)	0 (0)	14 (10)	.01	1 (1)	.007
Infectious PC, n (%)	66 (35)	13 (26)	53 (39)	.09	36 (30)	.39
Survival, n (%)				.006		<.001
Alive	143 (76)	46 (90)	97 (71)		110 (92)
Died	45 (24)	5 (10)	40 (29)		10 (8)
Death due to PC, n (%)	12 (6)	0 (0)	12 (9)	.04	0 (0)	.004

PC indicates pulmonary complications.

P value comparing patients in group 1 who did and did not normalize lung function.

^†

P value comparing patients in group 1 and group 2.

^‡

Severe acute GVHD grade II-IV.